In:
Ophthalmologica, S. Karger AG, Vol. 244, No. 4 ( 2021), p. 347-360
Abstract:
〈 b 〉 〈 i 〉 Purpose: 〈 /i 〉 〈 /b 〉 We aim to determine the effects of intravitreal aflibercept (IVA) on the mean sensitivity (MS) of the central retina, best-corrected visual acuity (BCVA), and central foveal thickness (CFT) in eyes with neovascular age-related macular degeneration (nAMD) with or without polypoidal choroidal vasculopathy (PCV). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 This was a prospective, interventional study. All eyes were treatment-naive with nAMD with or without PCV. Each eye received 3 monthly IVA injections followed by an IVA injection every 2 months for 12 months. The primary outcome was the change in the MS within the central 2°. The secondary outcomes were the changes in BCVA, CFT, greatest linear dimension (GLD), and percentage of eyes with a dry macula. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Thirty-seven eyes of 37 patients were studied. A significant improvement of the MS (dB) was observed +4.9 ± 4.6 dB (mean ± standard deviation) at 3 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), +5.5 ± 4.9 dB at 6 ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), and +7.0 ± 3.4 dB at 12 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001) compared to the baseline in all eyes. The MS of the eyes with non-PCV was not significantly different from that of eyes with PCV ( 〈 i 〉 p 〈 /i 〉 = 1.00, 1.00, 1.00, and 0.76 at baseline, 3, 6, and 12 M, respectively). The MS of 11 patients whose BCVA remained unchanged was significantly improved by +6.5 ± 2.8 dB at 3 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), +6.1 ± 4.3 dB at 6 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), and +6.4 ± 4.8 dB at 12 M ( 〈 i 〉 p 〈 /i 〉 = 0.003) compared to the baseline. The mean BCVA was significantly improved from the baseline to 3 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), 6 M ( 〈 i 〉 p 〈 /i 〉 = 0.027), and 12 M ( 〈 i 〉 p 〈 /i 〉 = 0.003) in all eyes. The BCVA was improved or maintained in 97% of the patients at 12 M. The mean CFT and GLD were significantly reduced at 12 M ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). Twenty-two eyes (71%) had a dry macula at 12 M. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 IVA administered by a fixed dosing regimen led to significant improvements of the central MS, BCVA, and macular morphology at 1 year in eyes with nAMD with or without PCV. These results were not significantly different between eyes with non-PCV and with PCV. The improvements of the MS of the retina of the central 2° in a subgroup whose BCVA remained unchanged through the 12-month experimental period was also significant. We conclude that the MS of the central 2° might be a better marker than the BCVA in determining the effectiveness of IVA treatments and might be helpful in determining early effects on the retina before BCVA changes can be detected.
Type of Medium:
Online Resource
ISSN:
0030-3755
,
1423-0267
Language:
English
Publisher:
S. Karger AG
Publication Date:
2021
detail.hit.zdb_id:
1483531-9
